Search

Search Results

• PO043 | MULTICENTRE REAL‑WORLD EXPERIENCE OF EMICIZUMAB PROPHYLAXIS IN AN ITALIAN COHORT OF 49 CHILDREN WITH SEVERE HEMOPHILIA A - EMIPED STUDY L. Pieri¹, B. Pollio², P. Giordano³, G. Lassandro⁴, S. Linari¹, R. Pasquino¹, E. Piellucci¹, MC. Di Stefano¹, F. Demartis¹, R. Fjerza¹, G. Castaman¹ | ¹Center for Bleeding Disorders, Careggi University Hospital, Firenze, Italy; ²Center for Inherited Bleeding and Thrombotic Disorders, Transfusion Medicine, "Regina Margherita" Children Hospital, Torino, Italy; ³Department of Interdisciplinary of Medicine, University of Bari 'Aldo Moro', Bari, Italy; ⁴General and Specialised Pediatrics Unit, "Giovanni XXIII" Hospital, University of Bari, Bari, Italy

  Lisa Pieri

  26-10-2026

  https://doi.org/10.4081/btvb.2026.859

  35

  PDF: 12

• BEST-05 | LONG-TERM EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A: REAL-WORLD EXPERIENCE ACROSS ALL AGES A. Colombo¹, I. Quaglia¹, M.R. Fasulo¹, C. Lodigiani¹, M.E. Mancuso^1|2 | ¹Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; ²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy

  Arianna Colombo

  14-10-2026

  https://doi.org/10.4081/btvb.2026.605

  146

  PDF: 17

• CO-80 | EMICIZUMAB PLASMA CONCENTRATIONS AND CLINICAL OUTCOMES IN ACQUIRED HEMOPHILIA A: A REAL-WORLD SINGLE-CENTER EXPERIENCE C. Simion^1|2, E. Zanon^1|2, C. Bulato¹, B. Stocco^1|2, F. Righetto¹, F. Sartorello¹, P. Simioni^1|2 | ¹First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Italy; ²Hemophilia Center, Padova University Hospital, Italy

  Chiara Simion

  14-10-2026

  https://doi.org/10.4081/btvb.2026.690

  56

  PDF: 17

• PO55 | Evaluation of safety and efficacy of emicizumab prophylaxis in pediatric patients with hemophilia A – a single centre experience M.L. Tramontano, M. Coppola, S. Coppola, M. Schiavulli | UOSD Centro Regionale Pediatrico Malattie della Coagulazione, Santobono Pausilipon Children Hospital, AORN, Napoli, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.324

  577

  PDF: 25

• CO-44 | EVALUATION OF THE DEVIATION BETWEEN PRESCRIBED AND RECOMMENDED EMICIZUMAB DOSING IN PATIENTS WITH CONGENITAL HEMOPHILIA A A.C. Giuffrida¹, S. Abeysinghe Gunawardhana¹, S. Amato², F. Casoli², C. Recchi², M. Saggioro², E. Bonetti³, M. Bodini¹, G. Poli² | ¹Centro Emofilia, UOC Medicina Trasfusionale, AOUI Verona, Italy; ²UOC Laboratorio Analisi, AOUI Verona, Italy; ³UOC Oncoematologia Pediatrica, AOUI Verona, Italy

  Marco Bodini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.654

  53

  PDF: 15

• PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.355

  758

  PDF: 26

• PO044 | UPDATING MANAGEMENT OF ACQUIRED HEMOPHILIA A USING EMICIZUMAB: REAL-WORLD OUTCOMES BY A COLLABORATIVE NETWORK OF 3 ITALIAN CENTERS MI. Tassoni¹, BM. Roccon¹, A. Dalla Salda², R. Benedetti³, R. Rossi⁴, C. Cattabiani⁴, G. Quintavalle¹, A. Casali², D. Imberti³, A. Coppola¹ | ¹SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; ²SOC Medicina Interna per acuti ad indirizzo metabolico ed emocoagulativo, Azienda USL IRCCS Reggio Emilia, Italy; ³Centro Emostasi e Trombosi, Medicina Interna, Azienda USL Piacenza, Italy; ⁴Lab. di Coagulazione, UOC Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Italy

  Antonio Coppola

  26-10-2026

  https://doi.org/10.4081/btvb.2026.860

  29

  PDF: 10

• CO-19 | A CASE OF LOSS OF EFFICACY OF EMICIZUMAB AFTER 6 YEARS OF REGULAR USE M.R. Fasulo¹, I. Quaglia¹, A. Colombo¹, C. Lodigiani¹, M.E. Mancuso^1|2 | ¹Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; ²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy

  Maria Rosaria Fasulo

  14-10-2026

  https://doi.org/10.4081/btvb.2026.629

  60

  PDF: 17
• 

  Influence of emicizumab on protein C-mediated clotting regulation

  Federica Mancazzo, Antonia Vitulli, Lavinia Dirienzo, Concetta T. Ammollo, Fabrizio Semeraro, Mario Colucci

  25-10-2023

  https://doi.org/10.4081/btvb.2023.89

  2657

  PDF: 450

  Supplementary Material: 141

• CO34 | Evaluation of emicizumab concentration and thrombin generation in a cohort of severe hemophilia A patients with and without inhibitor A. Taglietti¹, S. Ligia¹, F. Paoletti¹, R. Mormile¹, E. Baldacci², A. Chistolini¹, C. Santoro^1,2 | ¹Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; ²Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.241

  679

  PDF: 14

• CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients A. Cottonaro¹, S. Akula¹, B. Pollio², I. Ricca², T. Martini², J. Agnelli Giacchello³, P. Sciancalepore³, R. Santi³, A. Follenzi^1,3, S. Merlin¹ | ¹Università del Piemonte Orientale, Health Sciences, Novara; ²A.O. Città della Salute e della Scienza, SIMT Immunohematology and Transfusion Medicine Service, Diagnostic Department, Torino; ³Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.238

  648

  PDF: 17

• PO123 | PERIOPERATIVE MANAGEMENT OF FEMORAL FRACTURE SURGERY IN AN ELDERLY PATIENT WITH ACQUIRED HEMOPHILIA A RECEIVING EMICIZUMAB C. Simion, E. Zanon, B. Stocco, G. Saggiorato, F. Sartorello, C. Bulato, P. Simioni | Department of Medicine, University of Padova, Italy

  Chiara Simion

  26-10-2026

  https://doi.org/10.4081/btvb.2026.939

  27

  PDF: 11

• BEST-10 | CHANGES IN HYPERTROPHIC SYNOVIUM STATUS IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A RECEIVING EMICIZUMAB PROPHYLAXIS: THE RESOLVE STUDY I.L. Calcaterra¹, M. Di Minno¹, E. Baldacci², G. D’Errico¹, C. Santoro², A. Strangio³, S. Sorella², M. Leotta³, R.C. Santoro³ | ¹Department of Clinical Medicine and Surgery, Federico II University, Napoli, Italy; ²Haematology, University Hospital Policlinico Umberto I, Roma, Italy; ³Hemostasis and Thrombosis Centre, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy

  Ilenia Lorenza Calcaterra

  14-10-2026

  https://doi.org/10.4081/btvb.2026.610

  147

  PDF: 19

• PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.307

  633

  PDF: 21

• PO056 | SYNERGISTIC EFFECT OF RECOMBINANT FACTOR INFUSION ON THROMBIN GENERATION IN HEMOPHILIA PATIENTS UNDER EMICIZUMAB OR CONCIZUMAB PROPHYLAXIS F. Bocchi^1|2, R. Pastorino^1|2, M. Capetta^1|2|3, S. Bergonzi^1|2|3, G. Murante^1|2|3, F. Valeri^2|3, C. Dainese^2|3, A. Valpreda⁴, B. Bruno^1|3, A. Borchiellini^2|3 | ¹Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; ²Regional Center for Thrombotic and Hemorrhagic Diseases; ³Division of Hematology; ⁴Central Lab Baldi and Riberi, AOU Città della Salute e della Scienza di Torino, Italy

  Matilde Capetta

  26-10-2026

  https://doi.org/10.4081/btvb.2026.872

  30

  PDF: 11

• PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti¹, S. Ligia¹, F. Paoletti¹, R. Mormile¹, E. Baldacci², A. Chistolini¹, C. Santoro^1,2 | ¹Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; ²Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.285

  629

  PDF: 23

• CO-89 | FEMORAL FRACTURE SURGERY IN AN ELDERLY, FRAIL PATIENT WITH ACQUIRED HEMOPHILIA A RECEIVING EMICIZUMAB PROPHYLAXIS: A CASE REPORT C. Simion^1|2, E. Zanon^1|2, B. Stocco^1|2, F. Sartorello¹, C. Bulato¹, G. Saggiorato¹, P. Simioni^1|2 | ¹First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Italy; ²Hemophilia Center, Padova University Hospital, Italy

  Chiara Simion

  14-10-2026

  https://doi.org/10.4081/btvb.2026.699

  52

  PDF: 21

• PO040 | PHARMACODYNAMIC CHARACTERIZATION OF THROMBIN GENERATION IN SEVERE HEMOPHILIA A PATIENTS ON EMICIZUMAB PROPHYLAXIS: A REAL-WORLD LONGITUDINAL STUDY M. Bergamaschi, A. Pallotta, M. Biglietto, S. Sorella, S. Ligia, E. Baldacci, A. Chistolini, C. Santoro, R. Mormile | Department of translational and precision Medicine, Sapienza, University of Rome, Italy

  Martina Bergamaschi

  26-10-2026

  https://doi.org/10.4081/btvb.2026.856

  31

  PDF: 12

• PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.318

  669

  PDF: 26

• CO002 | RETROSPECTIVE LONGITUDINAL ASSESSMENT OF JOINT HEALTH AND QUALITY OF LIFE IN ADOLESCENT AND ADULT PATIENTS AFFECTED BY MODERATE OR SEVERE HAEMOPHILIA A WITH OR WITHOUT INHIBITOR SWITCHING FROM INTRAVENOUS FVIII TREATMENT TO SUBCUTANEOUS PROPHYLAXIS WITH EMICIZUMAB S. Ceglie¹, R. Gualtierotti^1|2, S. Arcudi¹, A. Ciavarella¹, S.M. Siboni¹, F. Peyvandi^1|2 | ¹Centro Emofilia e Trombosi Angelo Bianchi Bonomi, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy; ²Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milano, Italy

  Sara Ceglie

  26-10-2026

  https://doi.org/10.4081/btvb.2026.704

  156

  PDF: 14

• CO-39 | MYELOID CELL FUNCTION AND CYTOKINE PROFILES IN PEDIATRIC HEMOPHILIA A: INSIGHTS FROM FACTOR VIII AND EMICIZUMAB PROPHYLAXIS T. Martini¹, A. Cottonaro², S. Akula², B. Pollio¹, I. Ricca³, J. Agnelli Giacchello⁴, P. Sciancalepore⁴, R. Santi⁴, A. Follenzi^2|4, S. Merlin² | ¹Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; ²Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy; ³Transfusion Medicine, Ivrea Hospital, Ivrea, Italy; ⁴Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

  Tiziano Martini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.649

  61

  PDF: 14

• BEST-04 | MAJOR ORTHOPEDIC SURGERY WITH EMICIZUMAB: A SERIES OF 22 PATIENTS (40 PROCEDURES) WITH A MID-TERM FOLLOW-UP G. Daniele¹, C. Carulli¹, S. Linari², L. Pieri², G. Castaman² | ¹Clinica Ortopedica, Azienda Ospedaliero-Universitaria Careggi, Università degli Studi di Firenze, Italy; ²Centro Malattie Emorragiche e della Coagulazione, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy

  Giovanna Daniele

  14-10-2026

  https://doi.org/10.4081/btvb.2026.604

  139

  PDF: 14

• PO67 | Pancreatic cancer in a 71-year-old severe hemophilia A patient with inhibitors and sustained zero bleeding during emicizumab prophylaxis M. Biglietto, A.L. Faccini, S. Sorella, E. Crisanti, M. Antonacci, A. Taglietti, M. Gherardini, A. Tirnetta, S. Ligia, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.336

  672

  PDF: 30

• CO-37 | STEW-EFA STUDY: MULTICENTER EVALUATION OF ONE-STAGE AND CHROMOGENIC ASSAYS FOR EFANESOCTOCOG ALFA MEASUREMENT ON STAGO AND WERFEN PLATFORMS A.C. Molinari¹, M. Marchetti², A. Catalano³, L. Contino⁴, R. De Cristofaro⁵, A.B. Federici⁶, T. Martini⁷, I. Quaglia⁸, R. Rossi⁹, R. Santoro¹⁰, A. Tripodi¹¹, A. Valpreda¹² | ¹Regional Reference Centre for Hemorrhagic Diseases, Department of Hemato-Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy; ²Department of Immunohematology and Transfusion Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy; ³Società per la Promozione dell'educazione Medica (S.P.E.Me), Italy; ⁴Hemostasis and Thrombosis Unit, AOU SS Antonio e Biagio e C Arrigo, Alessandria, Italy; ⁵Dipartimento di Medicina e Chirurgia Traslazionale, Facoltà di Medicina e Chirurgia "Agostino Gemelli," Università Cattolica S. Cuore, Roma, Italy - Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario "A. Gemelli" Istituto di Ricerca e Cura a Carattere Scientifico, Roma, Italy; ⁶School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy; ⁷Hemophilia Centre, Immune-Hematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza", Torino, Italy; ⁸Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; ⁹Laboratory of Clinical Chemistry and Hematology, University Hospital of Parma, Italy; ¹⁰Hemophilia, Hemostasis, and Thrombosis Unit, Azienda Ospedaliero Universitaria Dulbecco, Catanzaro, Italy; ¹¹IRCCS Ca' Granda Maggiore Hospital Foundation and Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; ¹²Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Turin, Italy, reference laboratory of the Regional Center for Hemostasis and Thrombosis.

  Angelo Claudio Molinari

  14-10-2026

  https://doi.org/10.4081/btvb.2026.647

  43

  PDF: 17

• PO65 | Utilization of emicizumab in acquired hemophilia A: a case report C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, G. D’errico, L. Jr Valletta, M. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.334

  632

  PDF: 27

• CO-13 | USE OF THE MULTIDIMENSIONAL HEMOPHILIA PAIN QUESTIONNAIRE IN PATIENTS WITH SEVERE HEMOPHILIA A TREATED WITH EMICIZUMAB: A PILOT CROSS-SECTIONAL, SINGLE-CENTER STUDY I.L. Calcaterra, S. Donnarumma, G. D’Errico, C. De Luca, C. Caputo, P. Ciciola, E. Cimino, M. Di Minno | Università Federico II di Napoli, Italy

  Ilenia Lorenza Calcaterra

  14-10-2026

  https://doi.org/10.4081/btvb.2026.623

  100

  PDF: 16

• CO-62 | ACCESS TO ULTRA-LONG HALF-LIFE FACTOR VIII AS THE DEFINITIVE MOTIVATION FOR IMMUNE TOLERANCE INDUCTION IN THE ERA OF NON-REPLACEMENT THERAPIES B. Borsellino¹, T. Martini¹, I. Ricca², C. Linari³, B. Pollio¹ | ¹Paediatric Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital "Città della Salute e della Scienza", Torino, Italy; ²Transfusion Medicine, Ivrea Hospital, Ivrea, Italy; ³Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy

  Beatrice Borsellino

  14-10-2026

  https://doi.org/10.4081/btvb.2026.672

  50

  PDF: 17

• CO-57 | NXT007 PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS: COMBINED ANALYSIS OF TWO PHASE I/II MULTIPLE-ASCENDING-DOSE STUDIES M.E. Mancuso^1|2, M. Shima³, J.M. Staber⁴, Y.C. Chen⁵, F.J. López-Jaime⁶, M.C. Shen⁷, G. Ventriglia⁸, M. Takeyama⁹, C. Schmitt⁸, Y.S. Park¹⁰, A. Kiialainen⁸, N. Mizuno¹¹, M. Niggli⁸, T. Miyake¹¹, D. Matino¹², T. Saito¹¹, V. Jiménez-Yuste¹³, R. Kobayashi¹¹, D. Hart¹⁴, K. Nogami¹⁵ | ¹Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy; ²Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; ³Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Nara, Japan; ⁴Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, USA; ⁵Hemophilia Care and Research Center, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan; ⁶Servicio de Hematología, Hospital Universitario Regional de Málaga / Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain; ⁷Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; ⁸F. Hoffmann-La Roche Ltd, Basel, Switzerland; ⁹Division of Hemophilia, National Hospital Organization, Osaka National Hospital, Osaka, Japan; ¹⁰Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, South Korea; ¹¹Chugai Pharmaceutical Co., Ltd, Tokyo, Japan; ¹²McMaster University, Hamilton, Ontario, Canada; ¹³La Paz University Hospital-IdiPAZ, Autónoma University, Madrid, Spain; ¹⁴Roche Products Ltd, Welwyn Garden City, UK; ¹⁵Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan

  Maria Elisa Mancuso

  14-10-2026

  https://doi.org/10.4081/btvb.2026.667

  62

  PDF: 18

• PO127 | ANAPHYLACTIC REACTION TO RECOMBINANT ACTIVATED FVII IN A MILD HEMOPHILIA A PATIENT WITH INHIBITOR: A CASE REPORT I. Nichele, G. Carli, G. Marchesini, A. Tosetto | Haematology Department, S. Bortolo Hospital, Vicenza, Italy

  Ilaria Nichele

  26-10-2026

  https://doi.org/10.4081/btvb.2026.943

  25

  PDF: 14

• PO114 | A CASE OF ACQUIRED HEMOPHILIA AFTER TAVI AND CORONARY ANGIOPLASTY IN PATIENT WITH ATRIAL FIBRILLATION AND MULTIPLES CARDIOVASCULAR RISK FACTORS – THE ART AND SCIENCE OF THERAPEUTIC CONFLICT M.M. Poggi¹, C. Tamburini², M. Littera², M. Mazzetti² | ¹SOC Medicina 1, Nuovo Ospedale Prato, Prato, Italy; ²SOD Medicina Interna Interdisciplinare, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy

  Matteo Maria Poggi

  26-10-2026

  https://doi.org/10.4081/btvb.2026.930

  35

  PDF: 11

• CO-28 | SYNERGISTIC EFFECT OF RECOMBINANT FACTOR INFUSION ON THROMBIN GENERATION IN HEMOPHILIA PATIENTS UNDER EMICIZUMAB OR CONCIZUMAB PROPHYLAXIS F. Bocchi^1|2, R. Pastorino^1|2, G. Murante^1|2|3, S. Bergonzi^1|2|3, M. Capetta^1|2|3, F. Valeri^2|3, C. Dainese^2|3, A. Valpreda⁴, B. Bruno^1|3, A. Borchiellini^2|3 | ¹Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; ²Regional Centre for Thrombotic and Hemorrhagic Diseases, AOU Città della salute e della Scienza di Torino, Italy; ³Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; ⁴Central Lab Baldi and Riberi, AOU Città della salute e della Scienza di Torino, Italy

  Francesca Bocchi

  14-10-2026

  https://doi.org/10.4081/btvb.2026.638

  69

  PDF: 22

• CO-20 | REAL-WORLD EXPERIENCE ON THE MANAGEMENT OF MILD HEAD INJURY IN A COHORT OF CHILDREN WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS TREATED WITH EMICIZUMAB B. Pollio¹, B. Borsellino^1|2, T. Martini¹ | ¹Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; ²Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy

  Tiziano Martini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.630

  50

  PDF: 16
• 

  The changing landscape of treatment for acquired hemophilia A

  Massimo Franchini, Daniele Focosi

  30-01-2025

  https://doi.org/10.4081/btvb.2025.157

  2078

  PDF: 549

• PO115 | AL AMYLOIDOSIS IN A PATIENT WITH SEVERE HEMOPHILIA A AND INHIBITORS WHO HAD A MONOZYGOTIC TWIN: SAME GENES, DIFFERENT OUTCOMES M. Biglietto, S. Sorella, S. Ligia, C. Andriola, R. Mormile, E. Baldacci, A. Chistolini, C. Santoro | Sapienza, University of Rome, Italy

  Mario Biglietto

  26-10-2026

  https://doi.org/10.4081/btvb.2026.931

  30

  PDF: 12

• CO-58 | SUCCESSFUL TREATMENT WITH EFANESOCTOCOG ALFA OF INTRACRANIAL HEMORRHAGE IN A NEWBORN AFFECTED BY SEVERE HEMOPHILIA A T. Martini¹, B. Borsellino^1|2, B. Pollio¹ | ¹Hemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; ²Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy

  Tiziano Martini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.668

  59

  PDF: 14

• CO028 | ASSOCIATION BETWEEN BONE MARROW EDEMA AND JOINT PAIN IN HEMOPHILIC ARTHROPATHY: A RETROSPECTIVE SINGLE-CENTER STUDY R. Gualtierotti^1|2, E. Guido³, J. Acquati Lozej⁴, A. Giachi¹, M. Fassi¹, M.L. Franzone⁵, L.M. Gentile^5|6, S.M. Siboni¹, L.P. Solimeno⁴, F. Peyvandi^1|2 | ¹Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; ²Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy; ³Università degli Studi di Milano, Dipartimento di Oncologia ed EmatoOncologia, Milano, Italy; ⁴Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Orthopaedic Surgery and Traumatology, Milano, Italy; ⁵Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Radiology, Milano, Italy; ⁶Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-Oncologia, Milano, Italy

  Marco Fassi

  26-10-2026

  https://doi.org/10.4081/btvb.2026.730

  43

  PDF: 13
• 

  The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art

  Giovanni Di Minno, Gaia Spadarella, Ilenia Lorenza Calcaterra, Giancarlo Castaman, Paolo Simioni, Raimondo De Cristofaro, Cristina Santoro, Flora Peyvandi, Matteo Di Minno

  04-09-2024

  https://doi.org/10.4081/btvb.2024.144

  2095

  PDF: 361

  SUPPLEMENTARY MATERIAL: 219

• CO-30 | AL AMYLOIDOSIS IN A PATIENT WITH SEVERE HEMOPHILIA A AND INHIBITORS WHO HAD A MONOZYGOTIC TWIN: SAME GENES, DIFFERENT OUTCOMES M. Biglietto^1|2, S. Sorella¹, S. Ligia¹, C. Andriola¹, R. Mormile¹, E. Baldacci¹, A. Chistolini¹, C. Santoro¹ | ¹Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy; ²Department of Molecular Biology, Sapienza University of Rome, Italy

  Mario Biglietto

  14-10-2026

  https://doi.org/10.4081/btvb.2026.640

  53

  PDF: 19

• CO-78 | REAL-WORLD MANAGEMENT OF ACQUIRED HEMOPHILIA A: FOCUS ON RECOMBINANT PORCINE FVIII AS FIRST-LINE HEMOSTATIC TREATMENT AND LONG-TERM OUTCOMES M. Leotta, A. Strangio, A. Ierardi, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Centre, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy

  Marzia Leotta

  14-10-2026

  https://doi.org/10.4081/btvb.2026.688

  50

  PDF: 17

• CO21 | Viscoelastic testing in inherited bleeding disorders: a cross-sectional comparison between viscoelastic coagulation monitoring and rotational thromboelastometry C. Simion, C. Samà, C. Bulato, G. Gottardi, D. Regazzo, E. Campello, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.227

  652

  PDF: 20

• CO-36 | PLATELETS MATTER: THROMBIN GENERATION IN PLATELET‐RICH-PLASMA VS. PLATELET‐POOR‐PLASMA UNDER NON-REPLACEMENT THERAPIES IN HEMOPHILIA F. Bocchi^1|2, R. Pastorino^1|2, G. Murante^1|2|3, S. Bergonzi^1|2|3, M. Capetta^1|2|3, F. Valeri^2|3, C. Dainese^2|3, A. Valpreda⁴, B. Bruno^1|3, A. Borchiellini^2|3 | ¹Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; ²Regional Centre for Thrombotic and Hemorrhagic Diseases, AOU Città della salute e della Scienza di Torino, Italy; ³Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; ⁴Central Lab Baldi and Riberi, AOU Città della salute e della Scienza di Torino, Italy

  Francesca Bocchi

  14-10-2026

  https://doi.org/10.4081/btvb.2026.646

  56

  PDF: 15

• PO021 | PLATELETS MATTER: THROMBIN GENERATION IN PLATELET‐RICH PLASMA VERSUS PLATELET-POOR-PLASMA UNDER NON-REPLACEMENT THERAPIES IN HAEMOPHILIA F. Bocchi^1|2, R. Pastorino^1|2, G. Murante^1|2|3, S. Bergonzi^1|2|3, M. Capetta^1|2|3, F. Valeri^2|3, C. Dainese^2|3, A. Valpreda⁴, B. Bruno^1|3, A. Borchiellini^2|3 | ¹Department of Molecular Biotechnology and Health Sciences, University of Turin, Torino, Italy; ²Regional Centre for Thrombotic and Hemorrhagic Diseases; ³Division of Hematology; ⁴Central Lab Baldi and Riberi, AOU Città della salute e della Scienza di Torino, Torino, Italy

  Francesca Bocchi

  26-10-2026

  https://doi.org/10.4081/btvb.2026.837

  30

  PDF: 12

• CO-33 | REAL-WORLD EXPERIENCE WITH MARSTACIMAB PROPHYLAXIS IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS AND ADVANCED HEMOPHILIC ARTHROPATHY A. Casson¹, I. Ricca¹, A. Barchieri¹, G. Guido¹, M. Tucciarone¹, P. Ocello¹, C. Francisco², P. Abrate², G. Delios¹ | ¹Centro Malattie Trombotiche ed Emorragiche - SC Servizio Trasfusionale ASL TO4, Ivrea, Torino, Italy; ²SC Farmacia Ospedaliera ASL TO4, Ivrea, Torino, Italy

  Andrea Casson

  14-10-2026

  https://doi.org/10.4081/btvb.2026.643

  57

  PDF: 20